Saturday 17 October 2026
Export BIIB’s income statement to Excel — free account
Biogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
232.65
2.70
−1.15%
Follow BIIB
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
19.93 | 13.63 | 33.34 | 12.99 | 23.00 | 9.99 | 9.41 | 13.91 | 28.01 | 17.21 |
Piotroski F-Score |
4 | 6 | 4 | 5 | 5 | 6 | 6 | 7 | 5 | 5 |
Altman Z-Score |
3.13 | 2.83 | 3.50 | 4.30 | 3.51 | 3.87 | 4.78 | 5.42 | 6.11 | 5.90 |
P/S ratio |
2.61 | 2.30 | 3.94 | 3.89 | 3.26 | 2.93 | 3.86 | 4.58 | 5.79 | 5.56 |
P/FCF ratio |
12.77 | 8.85 | 31.35 | 22.98 | 10.64 | 10.71 | 8.66 | 11.63 | 27.45 | 16.51 |
Altman Z″-Score (non-manufacturers) |
5.67 | 4.78 | 4.67 | 6.14 | 4.57 | 4.87 | 5.56 | 5.90 | 6.14 | 6.37 |
Beneish M-Score |
(2.67) | (2.86) | (2.40) | (1.99) | (3.13) | (2.56) | (2.71) | (2.59) | (2.60) | (2.48) |
P/Operating CF |
50.37 | 29.26 | 3,099.01 | (226.36) | 42.67 | (107.32) | 28.32 | 32.53 | 46.79 | 40.27 |
P/B ratio |
1.41 | 1.33 | 2.62 | 2.96 | 3.26 | 3.69 | 4.16 | 4.73 | 5.64 | 5.25 |
Price to Tangible BV |
9.97 | 40.79 | 178.35 | 6.84 | 12.01 | 21.42 | 13.70 | 14.66 | 17.39 | 13.70 |
EV/Sales |
2.86 | 2.53 | 4.52 | 4.03 | 3.48 | 3.29 | 3.86 | 4.76 | 5.97 | 5.71 |
EV/EBITDA |
9.62 | 7.75 | 20.80 | 9.95 | 9.66 | 8.03 | 7.19 | 9.80 | 11.40 | 11.20 |
EV/Operating CF |
12.82 | 8.50 | 28.75 | 29.62 | 10.51 | 10.45 | 7.84 | 10.35 | 16.10 | 14.24 |
EV/FCF |
13.99 | 9.71 | 35.99 | 23.79 | 11.37 | 12.02 | 8.66 | 12.08 | 28.32 | 16.93 |
Quick Ratio |
1.54 | 0.68 | 0.79 | 2.02 | 1.25 | 1.21 | 1.31 | 1.67 | 1.63 | 1.85 |
Current Ratio |
2.68 | 1.35 | 2.00 | 2.99 | 1.83 | 1.84 | 1.72 | 2.32 | 2.34 | 2.55 |
Net Debt/EBITDA |
0.84 | 0.69 | 2.68 | 0.34 | 0.62 | 0.87 | 0.00 | 0.37 | 0.35 | 0.28 |
Debt/Assets |
21.35% | 16.21% | 25.29% | 25.58% | 26.28% | 30.16% | 16.37% | 23.47% | 25.09% | 28.47% |
Debt/Equity |
0.34 | 0.27 | 0.46 | 0.47 | 0.57 | 0.69 | 0.33 | 0.46 | 0.47 | 0.54 |
Asset Turnover |
0.34 | 0.35 | 0.38 | 0.42 | 0.45 | 0.52 | 0.55 | 0.55 | 0.53 | 0.54 |
Operating CF/Net income |
1.71 | 1.76 | 1.33 | 0.45 | 2.34 | 1.06 | 1.20 | 1.40 | 1.79 | 1.24 |
Capex/Depreciation |
(0.17) | (0.40) | (0.59) | 0.53 | (0.25) | (1.21) | (0.98) | (1.36) | (1.82) | (1.07) |
| 7.39% | 10.36% | 8.24% | 25.03% | 14.38% | 33.30% | 44.66% | 34.57% | 20.54% | 34.44% | |
| 4.50% | 5.95% | 4.52% | 12.58% | 6.42% | 15.43% | 22.42% | 18.11% | 10.91% | 17.47% | |
ROIC |
5.61% | 7.44% | 4.91% | 14.73% | 13.22% | 20.35% | 33.04% | 23.85% | 22.51% | 23.42% |
Return on Tangible Assets |
14.89% | 31.95% | 17.24% | 31.04% | 22.31% | 61.02% | 87.04% | 55.75% | 33.03% | 47.39% |
Average Days of Receivables |
49.54 | 52.99 | 61.75 | 61.17 | 51.50 | 51.96 | 47.74 | 53.14 | 53.14 | 45.96 |
Research and Development Expense of Revenue |
17.98% | 20.47% | 24.86% | 21.93% | 22.78% | 29.68% | 15.86% | 19.31% | 18.36% | 17.24% |
Selling, General and Administrative Expense of Revenue |
24.61% | 24.84% | 25.92% | 23.63% | 24.35% | 18.63% | 16.52% | 15.66% | 15.76% | 17.00% |
Intangible Assets out of Total Assets |
0.53 | 0.58 | 0.54 | 0.31 | 0.33 | 0.36 | 0.34 | 0.35 | 0.36 | 0.33 |
Share Based Compensation of Revenue |
2.94% | 3.01% | 2.69% | 2.50% | 2.17% | 1.47% | 1.27% | 1.17% | 1.04% | 1.35% |
Graham Net Nets |
(0.09) | (0.17) | (0.13) | (0.03) | (0.14) | (0.18) | (0.10) | (0.07) | (0.04) | (0.03) |
Graham Number |
157.35 | 170.24 | 135.94 | 208.61 | 131.34 | 191.34 | 224.86 | 175.97 | 126.12 | 145.53 |
Earnings Yield |
5.02% | 7.34% | 3.00% | 7.70% | 4.35% | 10.01% | 10.62% | 7.19% | 3.57% | 5.81% |
Free Cash Flow Yield |
7.83% | 11.30% | 3.19% | 4.35% | 9.40% | 9.34% | 11.54% | 8.60% | 3.64% | 6.06% |
Revenue per Share |
67.51 | 66.46 | 67.97 | 70.02 | 73.65 | 83.56 | 76.85 | 65.66 | 57.73 | 52.42 |
Operating CF per Share |
15.05 | 19.75 | 10.69 | 9.53 | 24.41 | 26.29 | 37.83 | 30.20 | 21.41 | 21.00 |
Capex per Share |
(1.27) | (2.47) | (2.15) | 2.34 | (1.86) | (3.43) | (3.58) | (4.32) | (9.23) | (3.33) |
Free Cash Flow per Share |
13.78 | 17.28 | 8.54 | 11.86 | 22.56 | 22.86 | 34.25 | 25.87 | 12.17 | 17.67 |
Cash per Share |
26.05 | 16.31 | 7.26 | 33.67 | 25.50 | 16.22 | 23.92 | 17.27 | 17.35 | 22.41 |
Shareholders Equity per Share |
124.62 | 114.81 | 102.28 | 92.14 | 73.51 | 66.41 | 71.29 | 63.60 | 59.26 | 55.53 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
124.62 | 114.81 | 102.28 | 92.14 | 73.51 | 66.41 | 71.29 | 63.60 | 59.26 | 55.53 |
Free Cash Flow |
2,019.20 | 2,515.70 | 1,235.80 | 1,723.70 | 3,363.00 | 3,678.00 | 6,409.10 | 5,301.60 | 2,588.20 | 3,859.50 |
Working Capital |
5,624.70 | 1,928.00 | 3,425.00 | 6,518.40 | 3,558.30 | 3,144.90 | 3,518.00 | 4,345.70 | 4,505.10 | 5,312.30 |
Capital Expenditures |
(185.40) | (359.80) | (311.40) | 339.40 | (276.90) | (551.80) | (669.50) | (886.10) | (1,962.80) | (727.70) |
Net Current Asset Value |
(2,208.60) | (3,876.50) | (5,186.10) | (1,374.50) | (5,061.10) | (7,045.70) | (5,513.40) | (4,616.40) | (3,181.20) | (2,016.00) |
EV/EBIT |
15.17 | 10.86 | 27.59 | 11.77 | 13.46 | 8.76 | 7.88 | 10.88 | 13.71 | 12.68 |
Capex to Sales |
0.02 | 0.04 | 0.03 | (0.03) | 0.03 | 0.04 | 0.05 | 0.07 | 0.16 | 0.06 |
Price to Operating Income |
13.85 | 9.90 | 24.03 | 11.37 | 12.59 | 7.81 | 7.88 | 10.47 | 13.29 | 12.37 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.35 | 0.28 | 0.16 | 0.19 | 0.33 | 0.13 | 0.21 | 0.18 | 0.34 | 0.27 |
Cash ROIC |
7.12% | 10.64% | 5.46% | 7.02% | 15.99% | 17.75% | 28.77% | 23.56% | 11.65% | 16.40% |
Accounts Receivable Turnover |
7.20 | 6.31 | 5.84 | 6.25 | 6.34 | 7.09 | 7.49 | 7.18 | 7.60 | 8.58 |
Accounts Payable Turnover |
5.62 | 5.58 | 5.66 | 4.22 | 4.04 | 3.66 | 4.34 | 4.74 | 4.83 | 5.40 |
Inventory Turnover |
1.04 | 0.93 | 1.31 | 1.69 | 1.74 | 1.93 | 2.26 | 1.98 | 1.71 | 1.56 |
Average Days of Payables |
65.59 | 67.02 | 58.11 | 78.74 | 101.94 | 91.98 | 99.08 | 74.45 | 88.56 | 69.07 |
Days of Inventory on Hand |
329.16 | 388.71 | 364.14 | 215.38 | 233.82 | 216.06 | 150.11 | 186.87 | 202.14 | 247.23 |
Average Receivables |
1,373.60 | 1,534.45 | 1,684.55 | 1,627.20 | 1,731.60 | 1,897.15 | 1,919.50 | 1,872.75 | 1,614.30 | 1,334.30 |
Average Payables |
428.10 | 413.75 | 447.40 | 540.35 | 522.05 | 492.85 | 450.65 | 383.00 | 337.65 | 273.60 |
Average Inventory |
2,314.30 | 2,493.95 | 1,935.90 | 1,347.95 | 1,210.05 | 936.40 | 867.05 | 916.30 | 952.15 | 947.50 |
Average Assets |
28,744.40 | 27,447.05 | 25,699.45 | 24,215.70 | 24,248.10 | 25,926.60 | 26,261.60 | 24,470.75 | 23,264.70 | 21,190.80 |
Average Common Equity |
17,486.40 | 15,757.70 | 14,093.90 | 12,174.05 | 10,822.90 | 12,012.60 | 13,185.35 | 12,814.85 | 12,363.35 | 10,751.75 |
Columns are period end dates